HM Payson & Co. boosted its stake in shares of Johnson & Johnson (NYSE:JNJ) by 1.2% during the first quarter, Holdings Channel reports. The firm owned 575,501 shares of the company’s stock after buying an additional 6,678 shares during the period. Johnson & Johnson makes up approximately 3.3% of HM Payson & Co.’s investment portfolio, making the stock its 3rd largest position. HM Payson & Co.’s holdings in Johnson & Johnson were worth $71,679,000 as of its most recent filing with the SEC.
Several other hedge funds have also recently bought and sold shares of the stock. State Street Corp boosted its stake in Johnson & Johnson by 4.3% in the first quarter. State Street Corp now owns 160,223,321 shares of the company’s stock valued at $19,955,806,000 after buying an additional 6,656,371 shares during the period. Norges Bank purchased a new stake in Johnson & Johnson during the fourth quarter valued at $3,220,322,000. Schwab Charles Investment Management Inc. boosted its stake in Johnson & Johnson by 1.8% in the first quarter. Schwab Charles Investment Management Inc. now owns 11,150,339 shares of the company’s stock valued at $1,388,775,000 after buying an additional 201,703 shares during the period. Fisher Asset Management LLC boosted its stake in Johnson & Johnson by 1.2% in the first quarter. Fisher Asset Management LLC now owns 11,093,898 shares of the company’s stock valued at $1,381,745,000 after buying an additional 136,764 shares during the period. Finally, Sumitomo Mitsui Trust Holdings Inc. boosted its stake in Johnson & Johnson by 0.5% in the first quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 7,948,942 shares of the company’s stock valued at $990,041,000 after buying an additional 42,144 shares during the period. 66.10% of the stock is owned by institutional investors and hedge funds.
Shares of Johnson & Johnson (JNJ) traded up 0.01% during midday trading on Friday, hitting $133.05. 1,596,894 shares of the stock were exchanged. Johnson & Johnson has a 12-month low of $109.32 and a 12-month high of $137.08. The firm has a market cap of $357.11 billion, a P/E ratio of 22.51 and a beta of 0.78. The firm has a 50 day moving average of $132.88 and a 200 day moving average of $126.90.
Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, July 18th. The company reported $1.83 EPS for the quarter, topping analysts’ consensus estimates of $1.79 by $0.04. Johnson & Johnson had a net margin of 22.52% and a return on equity of 26.76%. The business had revenue of $18.84 billion for the quarter, compared to analysts’ expectations of $18.94 billion. During the same period in the previous year, the company posted $1.74 earnings per share. The business’s revenue for the quarter was up 1.9% compared to the same quarter last year. Equities analysts forecast that Johnson & Johnson will post $7.18 EPS for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 12th. Stockholders of record on Tuesday, August 29th will be given a dividend of $0.84 per share. The ex-dividend date of this dividend is Friday, August 25th. This represents a $3.36 dividend on an annualized basis and a dividend yield of 2.53%. Johnson & Johnson’s payout ratio is currently 56.76%.
Several brokerages have recently commented on JNJ. BidaskClub upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 17th. Jefferies Group LLC restated a “hold” rating and issued a $135.00 price objective (down from $140.00) on shares of Johnson & Johnson in a report on Sunday, May 14th. Royal Bank Of Canada restated a “buy” rating and issued a $128.00 price objective on shares of Johnson & Johnson in a report on Thursday, June 15th. Atlantic Securities lowered shares of Johnson & Johnson from a “neutral” rating to an “underweight” rating and set a $113.00 price objective on the stock. in a report on Friday, July 21st. Finally, Morgan Stanley upped their price objective on shares of Johnson & Johnson from $135.00 to $140.00 and gave the stock an “overweight” rating in a report on Wednesday, July 5th. Three analysts have rated the stock with a sell rating, nine have assigned a hold rating and eleven have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus target price of $134.12.
In other news, VP Paulus Stoffels sold 102,692 shares of the business’s stock in a transaction on Monday, July 24th. The shares were sold at an average price of $133.14, for a total transaction of $13,672,412.88. Following the transaction, the vice president now directly owns 230,342 shares of the company’s stock, valued at $30,667,733.88. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, VP Dominic J. Caruso sold 82,591 shares of the business’s stock in a transaction on Thursday, July 20th. The stock was sold at an average price of $136.72, for a total transaction of $11,291,841.52. Following the transaction, the vice president now directly owns 226,693 shares in the company, valued at $30,993,466.96. The disclosure for this sale can be found here. Insiders own 0.19% of the company’s stock.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
